Knobler, R; Barr, M L; Couriel, D R; Ferrara, J L M; French, L E; Jaksch, P; Reinisch, W; Rook, A H; Schwarz, T; Greinix, H (2009). Extracorporeal photopheresis: past, present, and future. Journal of the American Academy of Dermatology, 61(4):652-665.
Full text not available from this repository.
Extracorporeal photopheresis (ECP) is a leukapheresis-based therapy that uses 8-methoxypsoralen and ultraviolet A irradiation. Used alone or in combination with biological agents, ECP is an established and effective therapy for advanced cutaneous T-cell lymphoma. ECP has also shown promising efficacy in a number of other severe and difficult-to-treat conditions, including systemic sclerosis, graft-versus-host disease, prevention and treatment of rejection in solid organ transplantation, and Crohn disease. Furthermore, the use of ECP in some of these conditions may allow a significant reduction in the use of systemic steroids and other immunosuppressants, reducing long-term morbidity and mortality. The accumulated experience shows ECP to be well tolerated, with no clinically significant side effects. Progress is also being made in the search for understanding of the mechanisms of action of ECP, which will ultimately facilitate improvements in the use of this therapy.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic|
|DDC:||610 Medicine & health|
|Deposited On:||08 Mar 2010 13:04|
|Last Modified:||27 Nov 2013 20:25|
|Citations:||Web of Science®. Times cited: 34|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page